Down 25%, should you buy the dip on Bristol Myers Squibb?

The pharma industry's dreaded patent cliff is a key driver of the stock's decline.
Nasdaq

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental ...

SC refuses stay on Zydus cancer drug launch, tells BMS to seek relief in HC

Supreme Court declines to stay Zydus Lifesciences' launch of biosimilar nivolumab, asks BMS to seek interim relief before ...
Seeking Alpha

Bristol Myers Squibb Canada Welcomes Positive CDA Recommendation for OPDIVO® Plus YERVOY® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer

Ontario becomes the first province to list the combination under the new FAST pilot program, supporting timely access for eligible patients "For thousands of Ontarians facing a cancer diagnosis, fast ...

Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength

Bristol-Myers Squibb Company hits a 52-week high as Breyanzi sales surge and AI imaging expands. Click for this updated look at BMY stock prospects.
Morningstar

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from ...